Processa Pharmaceuticals (PCSA) risk factors
Item 1A of every Processa Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors49 risks10 new2 dropped5 reworded
The company has added extensive new risks regarding a newly approved digital asset treasury reserve strategy, including custody, volatility, and SEC compliance. Financial disclosures show an accumulated deficit of $100.8 million at December 31, 2025, with cash expected to run out by the second quarter of 2026.
Filed Mar 18, 2026 - FY2024 10-K risk factors41 risks
Processa Pharmaceuticals relies on ongoing equity financing and faces substantial doubt about its ability to continue as a going concern with $1.2 million in cash at year-end 2024. Clinical development of cancer therapy drug candidates NGC-Cap, NGC-Gem, and NGC-Iri requires substantial capital and remains unproven. The company faces a potential Nasdaq delisting due to its common stock failing to maintain the $1.00 minimum bid price.
Filed Mar 20, 2025